The patient with CR was a 66-year-old male with EGFR mutation-positive NSCLC who had been heavily pretreated with five previous lines of therapy (including platinum- and taxane-based regimens with or without bevacizumab, and gefitinib). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.